找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Endocrine FGFs and Klothos; Makoto Kuro-o Book 2012 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer S

[復制鏈接]
樓主: FERN
21#
發(fā)表于 2025-3-25 05:16:20 | 只看該作者
Jeffrey M. Bumpous,Mary Worthenors is also different for this sub-family, requiring klotho protein cofactors rather than heparin sulfate proteoglycan. Mouse Fgf15 and human FGF19 play key roles in enterohepatic signaling, regulation of liver bile acid biosynthesis, gallbladder motility and metabolic homeostasis.
22#
發(fā)表于 2025-3-25 11:00:52 | 只看該作者
,Klotho and βKlotho,rs and exert their biological activities. This chapter overviews function of Klotho family proteins as obligate coreceptors for endocrine FGFs and discusses potential link between Klothos and age-related diseases.
23#
發(fā)表于 2025-3-25 12:10:22 | 只看該作者
24#
發(fā)表于 2025-3-25 18:03:53 | 只看該作者
25#
發(fā)表于 2025-3-25 20:05:08 | 只看該作者
26#
發(fā)表于 2025-3-26 00:47:07 | 只看該作者
27#
發(fā)表于 2025-3-26 07:42:13 | 只看該作者
Evidence for FGF23 Involvement in a Bone-Kidney Axis Regulating Bone Mineralization and Systemic Phs through yet-to-be defined locally derived factors. In addition, FGF23 production is regulated by 1,25(OH)2D in a feedback loop where FGF23 stimulate Cyp24 mediated degradation of 1,25(OH)2D that serves to protect the organism from the toxic effects of vitamin D excess. In this chapter, we will review the regulation and function of FGF23.
28#
發(fā)表于 2025-3-26 08:34:54 | 只看該作者
Book 2012 affinity to FGF receptors in their target organs, the endocrine FGFs have designated the Klotho family of transmembrane proteins as obligate co-receptors. By expressing Klothos in a tissue-specific manner, this unique co-receptor system also enables the endocrine FGFs to specify their target organs among many tissues that express FGF receptors.
29#
發(fā)表于 2025-3-26 15:07:12 | 只看該作者
30#
發(fā)表于 2025-3-26 17:51:39 | 只看該作者
https://doi.org/10.1007/978-3-662-33866-7 and lack of apparent side effects in a variety of animal models. Thus, FGF21 represents a novel and appealing therapeutic reagent for Type 2 diabetes mellitus, obesity, dyslipidemia, cardiovascular and fatty liver diseases. The in vitro biology, genetic animal models and in vivo pharmacology of FGF21 will be discussed in this chapter.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-29 09:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
怀安县| 桂东县| 蒙山县| 大连市| 海城市| 新竹县| 茶陵县| 清河县| 富民县| 仙居县| 满洲里市| 翁牛特旗| 霍山县| 江阴市| 五峰| 冀州市| 新化县| 米易县| 广南县| 红桥区| 平塘县| 潼南县| 北宁市| 工布江达县| 麻阳| 石棉县| 县级市| 牟定县| 锡林浩特市| 启东市| 玛沁县| 马鞍山市| 泰来县| 尼木县| 清远市| 玉山县| 六安市| 孟村| 扬中市| 南康市| 上林县|